Capucine Daridon
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.
Journal: Journal of cell communication and signaling
Published: March 08, 2016
Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: June 09, 2015
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Journal: Arthritis research & therapy
Published: January 27, 2015
Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation.
Journal: Arthritis research & therapy
Published: May 09, 2014
Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 23, 2013
Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia.
Journal: Blood
Published: September 08, 2012
CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Journal: Arthritis and rheumatism
Published: December 29, 2011
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Journal: Arthritis research & therapy
Published: November 06, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026